The January/February issue of NeuroPerspective for 2017 has now been published. The issue is our Annual Overview of the neurotherapeutics sector, with capsule reviews for 110 CNS companies of all sizes, a review of deal and funding trends; Highlights and Lowlights from 2016; as well as an assessment of major events coming up this year. The review provides insightful, candid commentary about a wide range of issues pertinent to the development of therapeutics for neurology and psychiatry, including the current climate for investment and partnership funding; an updated assessment of the amyloid hypothesis in Alzheimer’s; US governmental elements to be monitored; threats to the credibility of the biopharma industry; the prospects for single-pivotal trial NDAs; pharma pricing missteps; a Company Spotlight Review for EIP Pharma; and many more topics.
Some of the companies included in the Annual Overview are:
Acadia Pharmaceuticals, AC Immune, Acorda Therapeutics, Adamas Pharmaceuticals, AgeneBio, Alcobra, Alector, Alkahest, Alkermes, Allergan, Alzheon, American Life Sciences Pharmaceutical, Amgen, AMO Pharma, Amorsa Therapeutics, Anavex Life Sciences, Anelixis Therapeutics, Annexon, Aptinyx, Asceneuron, Astellas, AstraZeneca, Avanir, AveXis, Axial Biotherapeutics, Axon-Neuroscience, Axovant, Axsome, Azevan, BioAxone, Biogen, Biohaven Pharmaceuticals, Bionomics, Blackthorn Therapeutics, Boehringer Ingelheim, BrainStorm Cell Therapeutics, Cara Therapeutics, Catalyst Pharmaceuticals, Centrexion, Cerecor, Cortexyme, Denali Therapeutics, Depomed, Egalet, EIP Pharma, Eisai, Embera Therapeutics, Evotec, Flex Pharma, Genentech, Gliacure, GSK, GW Pharmaceuticals, Heptares Therapeutics, Intra-Cellular Therapies, Innate Immunotherapeutics, Ionis Pharmaceuticals, JNJ/Janssen, Lilly, Lundbeck, Lysosomal Therapeutics, Marinus Pharmaceuticals, MedGenics, Merck, Methylation Sciences, Minerva Neurosciences, Mitsubishi Tanabe, Neuren Pharmaceuticals, Neurocrine Biosciences, Newron, Novartis, Otsuka, Ovid Therapeutics, Pfizer, Prana Biotechnology, Probiodrug, Proclara Biosciences, Purdue Pharma, ReNeuron, RespireRx, Roche, SAGE Therapeutics, Sanofi/Genzyme, Sunovion, Supernus, Takeda,TauRx, Tetra Discovery,Teva Pharmaceuticals,Trevena, UCB Pharma, Voyager Therapeutics, Wex Pharma, Xenon, Yumanity Therapeutics, Zogenix, Zynerba.
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.
A one-year (1-5 user) subscription to NeuroPerspective is $2600. Special startup and academic pricing is available. The Annual Overview issue of NeuroPerspective is being made available as a single-issue purchase for $400.
NI Research also publishes NeuroLicensing, the 2016-17 edition comprehensively reviews current licensing trends in the CNS area, and assesses large and midsize pharma companies in terms of their licensing agendas and performance.
NI Research’s Second Opinion provides consulting services to the pharma industry on strategic direction and licensing.
